Mending a broken heart with biotech

French company CellProthera has seen some remarkable results treating people who have had a heart attack.  On this week’s podcast, the company’s CEO Matthieu de Kalbermatten tells us how it works.

01:00-03:29: About CellProthera
03:30-06:30: What are ProtheraCytes?
06:30-09:02: Is this a cure?
09:02-10:24: Is prevention the best option?
10:25-11:49: Is this therapy useful to treat other conditions?
11:50-13:55: How quickly do you need to treat a patient?
13:56-16:39: The field of regenerative therapy
16:39-17:52: Is regenerative therapy a growing sector?
17:53-18:26: Clinical trials
18:26-19:22: Upcoming phase 3 trials
19:22-20:36: The regulatory pathway
20:37-23:25: Cost and scale
23:25-24:20: The need for partnerships
24:21-24:57: Next steps
24:57-28:30: Is there excitement in the medical field for this treatment?

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

Stay updated by subscribing to our newsletter

Chapters

• 1:00 The history of CellProthera
• 3:30 What are ProtheraCytes?
• 6:30 Is this a cure?
• 9:02 Is prevention the best option?
• 10:25 Is this process useful in other conditions?
• 11:50 How quickly do you need to treat a patient?
• 13:56 The field of regenerative therapy
• 16:39 Is regenerative therapy a growing sector?
• 17:53 Clinical trials
• 18:26 Upcoming phase 3 trials
• 19:22 The regulatory pathway
• 20:37 Cost and scale
• 23:25 The need for partnerships
• 24:21 What are the next steps?
• 24:57 Is there excitement in the medical field for this treatment?